Charles River Laboratories International, Inc. today announced the launch of its nAAVigation™ Vector Platform. nAAVigation TM Vector Platform: Accelerating Your AAV Pathway to GMP and Clinic ...

Charles River Laboratories International, Inc. CRL recently announced the introduction of its Modular and Fast Track viral vector technology (tech) transfer frameworks. With decades of experience ...

Charles River Laboratories has entered an agreement with German company Captain T Cell to focus on the production of plasmid DNA and retrovirus vectors for gene-modified cell therapy. The ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral ...

Charles River launches nAAVigation Vector Platform, with the capability to reduce viral vector gene therapy program timelines to GMP by 55%.

Leveraging decades of Adeno-Associated Virus (AAV) vector contract development and manufacturing (CDMO) experience and biologics testing expertise, Charles River has established a platform which ...